TY - JOUR
T1 - Quiescent cancer cells
T2 - Therapeutic targets to overcome immunotherapy resistance?
AU - Emens, Leisha
AU - Cimino-Mathews, Ashley
N1 - Funding Information:
LAE has been supported by research funding to the institution from Abbvie, Aduro Biotech, AstraZeneca, the Breast Cancer Research Foundation, Bristol Myers Squibb, Bolt Therapeutics, Compugen, Corvus, CytomX, the US Department of Defense, EMD Serono, Genentech, Immune Onc, Maxcyte, Merck, the National Cancer Institute, Next Cure, the NSABP Foundation, SU2C, Silverback, Roche, the Translational Breast Cancer Research Consortium, Takeda, Tempest, and HeritX. ACM is supported by research funding from Bristol-Myers Squibb. LAE has participated on advisory boards and/or received consulting fees from Genentech, F Hoffman La Roche, Chugai, GPCR, Gilead, Immutep, Immune Onc, Mersana, and Shionogi; she has received royalties from Aduro Biotech. LAE has participated on the steering committee for IMpassion130, KATE2, and KATE3. She is the current Vice President of the Society for the Immunotherapy of Cancer. ACM has received consulting fees from Bristol-Myers Squibb and Roche.
Funding Information:
LAE has been supported by research funding to the institution from Abbvie , Aduro Biotech , AstraZeneca , the Breast Cancer Research Foundation , Bristol Myers Squibb , Bolt Therapeutics , Compugen , Corvus , CytomX , the US Department of Defense , EMD Serono , Genentech , Immune Onc , Maxcyte, Merck, the National Cancer Institute, Next Cure, the NSABP Foundation, SU2C, Silverback, Roche, the Translational Breast Cancer Research Consortium, Takeda, Tempest, and HeritX. ACM is supported by research funding from Bristol-Myers Squibb.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/6/10
Y1 - 2022/6/10
N2 - Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor clinical outcomes. Chemoimmunotherapy improves outcomes in high-risk, early-stage disease, but not all patients benefit. Baldominos and colleagues1 drill down into early TNBC sub-microenvironments using single-cell technologies, characterizing quiescent cancer cell niches that may drive immunotherapy resistance and disease relapse.
AB - Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor clinical outcomes. Chemoimmunotherapy improves outcomes in high-risk, early-stage disease, but not all patients benefit. Baldominos and colleagues1 drill down into early TNBC sub-microenvironments using single-cell technologies, characterizing quiescent cancer cell niches that may drive immunotherapy resistance and disease relapse.
UR - http://www.scopus.com/inward/record.url?scp=85131661547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131661547&partnerID=8YFLogxK
U2 - 10.1016/j.medj.2022.05.013
DO - 10.1016/j.medj.2022.05.013
M3 - Comment/debate
C2 - 35690055
AN - SCOPUS:85131661547
SN - 2666-6359
VL - 3
SP - 358
EP - 360
JO - Med
JF - Med
IS - 6
ER -